Recent abolon transactions

Abolon advises Renaissance on its investment in Baitella AG

The Renaissance Investment Foundation has become a majority shareholder in Baitella AG. Together with the management, Renaissance will develop the globally successful quality products for medical applications under the “Fisso” brand. Baitella AG was founded by Carlo Baitella in 1978 and, with its Fisso products, is the world's leading supplier of high-quality articulated tripods. The company supplies both the medical and industrial segments with articulated tripods and accessories in standard and customer versions. Abolon has advised Renaissance investment with a team of specialist advisors on this transaction.

Read more

Healthcare insights

How will new landmark legislation affect Germany’s private hospital groups

The new Hospital Structure Act could force small, low quality public sector hospitals to the wall. But it could also cap growth for big private operators. We examine likely scenarios.

Read more

Healthcare deal of the month

December 2015: Etac acquires Convaid

The Deal: In December 2015, Etac, a Sweden-based developer and manufacturer of mobility solutions and rehab products, acquired Convaid Products

Read more

WELCOME TO ABOLON

Abolon is a strategy consulting and corporate finance company with an exclusive focus on the healthcare sector.

We pride ourselves on our specialist insights into the various segments of the healthcare markets in Europe and beyond.

Our global network in the healthcare sector provides us with unmatched dealflow of large and mid-sized healthcare opportunities.

Facts & figures

  • Healthcare forms an enormous ...
  • Stable healthcare sector attracts ...
  • The global pharmaceutical market ...
  • The healthcare sector offers ...
  • Abolon has advised on ...
  • Healthcare forms an enormous part of developed country's economy, contributing over 10 percent of gross domestic product (GDP).
  • Stable healthcare sector attracts record private equity investments.
  • The global pharmaceutical market is expected to grow from 995 $bn in 2011 to 1160 $bn in 2016
  • The healthcare sector offers numerous opportunities at low risk
  • Abolon has advised on 4 successful healthcare transactions in the last 18 months.